Prospective evaluation of 18 F-FACBC PET/CT and PET/MRI versus multiparametric MRI in intermediate- to high-risk prostate cancer patients (FLUCIPRO trial).

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: Springer-Verlag Berlin Country of Publication: Germany NLM ID: 101140988 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1619-7089 (Electronic) Linking ISSN: 16197070 NLM ISO Abbreviation: Eur J Nucl Med Mol Imaging Subsets: MEDLINE
    • Publication Information:
      Original Publication: Berlin : Springer-Verlag Berlin, 2002-
    • Subject Terms:
    • Abstract:
      Purpose: The purpose of this study was to evaluate 18 F-FACBC PET/CT, PET/MRI, and multiparametric MRI (mpMRI) in detection of primary prostate cancer (PCa).
      Methods: Twenty-six men with histologically confirmed PCa underwent PET/CT immediately after injection of 369 ± 10 MBq 18 F-FACBC (fluciclovine) followed by PET/MRI started 55 ± 7 min from injection. Maximum standardized uptake values (SUV max ) were measured for both hybrid PET acquisitions. A separate mpMRI was acquired within a week of the PET scans. Logan plots were used to calculate volume of distribution (V T ). The presence of PCa was estimated in 12 regions with radical prostatectomy findings as ground truth. For each imaging modality, area under the curve (AUC) for detection of PCa was determined to predict diagnostic performance. The clinical trial registration number is NCT02002455.
      Results: In the visual analysis, 164/312 (53%) regions contained PCa, and 41 tumor foci were identified. PET/CT demonstrated the highest sensitivity at 87% while its specificity was low at 56%. The AUC of both PET/MRI and mpMRI significantly (p < 0.01) outperformed that of PET/CT while no differences were detected between PET/MRI and mpMRI. SUV max and V T of Gleason score (GS) >3 + 4 tumors were significantly (p < 0.05) higher than those for GS 3 + 3 and benign hyperplasia. A total of 442 lymph nodes were evaluable for staging, and PET/CT and PET/MRI demonstrated true-positive findings in only 1/7 patients with metastatic lymph nodes.
      Conclusions: Quantitative 18 F-FACBC imaging significantly correlated with GS but failed to outperform MRI in lesion detection. 18 F-FACBC may assist in targeted biopsies in the setting of hybrid imaging with MRI.
    • References:
      J Natl Compr Canc Netw. 2015 Dec;13(12 ):1534-61. (PMID: 26656522)
      Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1258-1268. (PMID: 28497198)
      Radiology. 2014 Mar;270(3):849-56. (PMID: 24475804)
      Radiology. 1983 Sep;148(3):839-43. (PMID: 6878708)
      Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):941-949. (PMID: 28138747)
      J Nucl Med. 2013 Jul;54(7):1007-10. (PMID: 23708197)
      Magn Reson Imaging. 2015 Dec;33(10 ):1212-1218. (PMID: 26220861)
      Eur J Nucl Med Mol Imaging. 2016 May;43(5):889-97. (PMID: 26592938)
      Eur J Radiol. 2012 Nov;81(11):2966-72. (PMID: 22342610)
      J Nucl Med. 2010 Nov;51(11):1676-83. (PMID: 20956477)
      Acta Radiol. 2016 Apr;57(4):487-93. (PMID: 25907118)
      Cancer Chemother Rep. 1966 Mar;50(3):125-8. (PMID: 5948714)
      Anticancer Res. 2003 Jul-Aug;23 (4):3413-8. (PMID: 12926082)
      Clin Cancer Res. 2011 Jun 1;17 (11):3751-9. (PMID: 21493868)
      Magn Reson Med. 2016 Jan;75(1):337-44. (PMID: 25733132)
      Magn Reson Med. 2015 May;73(5):1954-69. (PMID: 25045885)
      Int Braz J Urol. 2009 Sep-Oct;35(5):559-64. (PMID: 19860934)
      Cancer Sci. 2008 Dec;99(12):2380-6. (PMID: 19018776)
      Eur J Nucl Med Mol Imaging. 2013 Jul;40 Suppl 1:S72-8. (PMID: 23503575)
      Am J Surg Pathol. 2005 Sep;29(9):1228-42. (PMID: 16096414)
      Eur Urol. 2013 Jul;64(1):106-17. (PMID: 23628493)
      Transl Androl Urol. 2017 Jun;6(3):472-482. (PMID: 28725589)
      J Urol. 2010 Feb;183(2):433-40. (PMID: 20006878)
      Med Phys. 2011 Oct;38(10 ):5394-411. (PMID: 21992359)
      Eur J Nucl Med Mol Imaging. 2011 Jan;38(1):138-52. (PMID: 20922522)
      J Nucl Med. 2012 Apr;53(4):538-45. (PMID: 22343504)
      Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1014-1024. (PMID: 28283702)
      Radiology. 2013 Nov;269(2):482-92. (PMID: 23788719)
      Clin Cancer Res. 2013 Oct 1;19(19):5434-43. (PMID: 23935037)
      Nucl Med Biol. 2000 Oct;27(7):661-70. (PMID: 11091109)
      Magn Reson Med. 2016 May;75(5):2130-40. (PMID: 26094849)
      Magn Reson Med. 2015 Oct;74(4):1116-24. (PMID: 25329932)
      Magn Reson Med. 2015 May;73(5):1988-98. (PMID: 25046482)
      J Magn Reson Imaging. 2015 May;41(5):1394-404. (PMID: 24956412)
      Am J Nucl Med Mol Imaging. 2013;3(1):85-96. (PMID: 23342303)
      Eur J Nucl Med Mol Imaging. 2016 Aug;43(9):1601-10. (PMID: 26960562)
      J Magn Reson Imaging. 2017 Oct;46(4):1089-1095. (PMID: 28165653)
      Pathol Int. 2009 Jan;59(1):7-18. (PMID: 19121087)
      CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30. (PMID: 26742998)
      Acad Radiol. 2000 Jun;7(6):413-9. (PMID: 10845400)
      J Magn Reson Imaging. 2014 May;39(5):1213-22. (PMID: 24127398)
      Radiographics. 2016 Jan-Feb;36(1):142-59. (PMID: 26587888)
    • Contributed Indexing:
      Keywords: 18F-FACBC; Diffusion-weighted imaging; PET/CT; PET/MRI; Prostate cancer
    • Molecular Sequence:
      ClinicalTrials.gov NCT02002455
    • Accession Number:
      0 (Carboxylic Acids)
      0 (Cyclobutanes)
      38R1Q0L1ZE (fluciclovine F-18)
    • Publication Date:
      Date Created: 20171118 Date Completed: 20181009 Latest Revision: 20181113
    • Publication Date:
      20240105
    • Accession Number:
      10.1007/s00259-017-3875-1
    • Accession Number:
      29147764